NASDAQ •
Healthcare •
Biotechnology •
Quote as of 07/02/2026
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization242.8 mln
Float89.78 mln
Earnings Date08/11/2026
Piotroski F-Score
3
/ 9
Below average
1-Year Forecast
20.00
Transformational upside
Relative Strength
73
/ 100
Outperforming
Debt / Equity
0.00
Debt-free
ROE
-38.18
Deeply negative
Dividend Yield
0.00%
No dividend
Business Description
Anavex Life Sciences Corp. is a drug development company focused on finding new treatments for brain and nervous system conditions, including Alzheimer's disease, Parkinson's disease, Rett syndrome, and certain cancers. Its most advanced compound, blarcamesine, is a pill designed to support healthy cell function and has been tested in multiple clinical trials across several of these conditions. The company is also advancing a second drug candidate that has shown promise in slowing the progression of Alzheimer's disease in laboratory studies. Founded in 2004, Anavex is headquartered in New York City.
